

Cell Reports, Volume 42

Supplemental information

**Ectopic expression of DOCK8 regulates
lysosome-mediated pancreatic tumor cell invasion**

Omar L. Gutierrez-Ruiz, Katherine M. Johnson, Eugene W. Krueger, Roseanne E. Nooren, Nicole Cruz-Reyes, Carrie Jo Heppelmann, Tara L. Hogenson, Martin E. Fernandez-Zapico, Mark A. McNiven, and Gina L. Razidlo


Supplementary Information

Figure S1. Generation of TMEM192-HA stable cells for lysosome proteomic analysis and validation of KRAS-mediated DOCK8 expression and localization to lysosomes.


Related to Figure 1.

A, Immunoblotting for HA following lentiviral transduction of TMEM192-HA construct into iKRAS^{G12D} cells. GAPDH serves as loading control. **B**, Immunofluorescence staining of LAMP1 (green) and HA (TMEM192-HA, red) in TMEM192-HA iKRAS^{G12D} cells. Nuclei were labeled with Hoechst (blue). Scale bar, 10 μ m. **C**, Immunoblotting of whole cell lysates (WCL) and lysosomes isolated from control or TMEM192-HA iKRAS^{G12D} cells cultured with doxycycline (KRAS^{G12D}, 1 μ g/ml) or following 72-hour doxycycline withdrawal (WT). Purity and integrity of isolated lysosomes was validated by immunoblotting for lysosome markers (TMEM192-HA, LAMP2A, cathepsin B), lysosome binding proteins (mTOR, Rab7), and non-lysosome markers (GM130, Golgi; COXIV, Mitochondria). Induction of KRAS^{G12D} expression was validated by immunoblotting of phosphorylated ERK (pERK) and total ERK. **D**, Immunoblotting of DOCK8 in whole cell lysates (WCL) and lysosomes isolated from control or TMEM192-HA Panc04.03 cells. Purity and integrity of isolated lysosomes was validated by immunoblotting for lysosome markers (LAMP1, cathepsin B), and non-lysosome marker (COXIV, Mitochondria). Images of DOCK8-YFP (green) localizing to lysotracker labeled lysosomes (red) in **E**, iKRAS^{G12D} and **F**, Panc04.03 cells. Scale bar, 5 μ m (E) or 10 μ m (F). **G**, Immunoblotting and **H**, Quantitation of KRAS protein levels in iKRAS^{G12D} cells cultured with or without doxycycline as indicated above. Induction of KRAS^{G12D} expression was validated by immunoblotting of pERK and total ERK, and GAPDH served as loading control. **I**, Immunoblotting and **J**, Quantitation of iKRAS^{G12D} cells transfected with HA control or WT-KRAS-HA or treated with and without doxycycline as described above. **K**, DOCK8 is not degraded by lysosomes. Immunoblotting of DOCK8 in TMEM192-HA iKRAS^{G12D} expressing WT or KRAS^{G12D} following treatment with BafilomycinA1 (Baf, 1 μ M) for 0, 12, and 24 hours. p62 is a positive control for a cargo degraded by lysosomes, and GAPDH serves as a loading control. Graphs show the mean \pm S.E.M of at least three independent biological replicates. P-values were calculated using a Students t-test. ns, $p > .05$; *, $p \leq 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p \leq 0.0001$.


A



B



D



C




Figure S2. DOCK8 CRISPR knockout impairs tumor progression and metastatic invasion *in vivo*

Related to Figure 2

A, Immunofluorescence staining of Actin (red) in mKPC control or DOCK8 CRISPR knockout clones 1-3. Nuclei were labeled with Hoechst (blue). Scale bar, 10 μ m. **B**, **C**, Representative images of C57Bl/6J mice following pancreatic orthotopic injection of control (clone 1 or 3) or DOCK8 knockout (clone 1 or 2) in **B**, male and **C**, female. Image panel includes a general picture of each mouse, resected pancreas (P) with primary tumor (T) attached to the spleen (scale bar 1cm), H&E staining of normal pancreas, primary and metastatic tumors (scale bar 50 μ m). **D**, Control or DOCK8 knockout primary tumors from male and female mice. Scale bar, 1cm.




Figure S3. DOCK8 is required for cell invasion but dispensable for cell migration.

Related to Figure 2

A, Immunoblotting and **B**, Relative DOCK8 mRNA levels by qRT-PCR confirming DOCK8 knockdown by individual DOCK8si1 and DOCK8si2 and DOCK8siP in mKPC, 6741-P, and L3.6 cells. **C**, Quantitation of % transwell invasion following DOCK8 knockdown by the indicated siRNAs in mKPC, 6741-P, and L3.6 cells. A total of at least 500 cells were counted per condition on the top and bottom of the transwell filter followed by calculation of % of invasion. **D**, Quantitation and **E**, Images of wound healing cell migration at 0 and 8 hours in nontargeting (NT) control and DOCK8 knockdown (DOCK8si1 and 2) mKPC, 6741-P, and L3.6 cells. **F**, Quantitation and **G**, Images of wound healing cell migration at 0 and 8 hours in control and DOCK8 CRISPR knockout mKPC cells clones 1-3. **H**, Images and **I**, Quantitation of wound healing cell migration at 0 and 8 hours in Panc1 cells stably expressing Flag, Flag-DOCK8, or Flag-DOCK8-V1985A (GEF inactive). Cell migration area is graphed (μm^2). Scale bar, 200 μm . **J**, Immunoblotting of DOCK8 in mKPC cells following lentiviral transduction of Flag, Flag-DOCK8, or Flag-DOCK8-V1985 (GEF inactive). **K**, Quantitation of transwell cell invasion assay of mKPC cells described in **J**. Cells were seeded on matrigel coated transwell filters and allowed to invade for 20 hours towards a high serum gradient. A total of 1500 cells were quantitated per condition across 3 experiments. **L-N**, Immunoblotting and quantitation of EMT markers E-Cadherin, N-Cadherin, and Vimentin in DOCK8 knockdown (DOCK8si1, 2, or DOCK8siP) mKPC, 6741-P, and L3.6 cells. GAPDH serves as loading control. Validation of DOCK8 knockdown in these cells is shown in figure S7H. Graphs show the mean \pm S.E.M of at least three independent biological replicates. P-values were calculated using a Student's t-test. One-way ANOVA with the Tukey's post hoc test was used for comparison of the means of more than 2 datasets (**F**). ns, $p > .05$; *, $p \leq 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p \leq 0.0001$.




Figure S4. Minimal effects on cell viability upon DOCK8 depletion

Related to Figure 2

A, DOCK8 immunoblotting in 6741-P DOCK8 knockdown cells **B**, Quantification of crystal violet staining of 6741-P cells following DOCK8 knockdown. **C**, MTS cell viability assay of 6741-P cells following DOCK8 knockdown. **D**, DOCK8 immunoblotting in L3.6 DOCK8 knockdown cells **E**, Quantification of crystal violet staining of L3.6 cells following DOCK8 knockdown. **F**, MTS cell viability assay of L3.6 cells following DOCK8 knockdown. **G**, Crystal violet staining and **H**, MTS cell viability assay of control and DOCK8 CRISPR knockout mKPC cells (clones 1-3). **I**, Propidium iodide FACS assessment of cell cycle distribution of control and DOCK8 CRISPR knockout mKPC cells. **J**, Immunoblotting for the apoptosis marker cleaved and total caspase 3 in control and DOCK8 CRISPR knockout mKPC cells (clones 1-3). Treatment of control clone 1 with staurosporine (1 μ M) for 16 hours served as an apoptosis positive control. GAPDH serves as loading control. **K**, Quantitation of Cleaved caspase-3 fold change normalized to GAPDH. Individual fold changes were normalized to the average of control clones 1-3 (dotted line). **L**, Crystal violet staining and **M**, MTS cell viability assay of Flag, Flag-DOCK8, or Flag-DOCK8-V1985 Panc1 stable cells. Graphs show the mean \pm S.E.M of three independent biological replicates. P-values were calculated using a Student's t-test. One-way ANOVA with the Tukey's post hoc test was used for comparison of the means of more than 2 datasets (**G, H K**). ns, $p > .05$; *, $p \leq 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p \leq 0.0001$.




Figure S5. DOCK8 regulates lysosome size and motility in pancreatic cancer cells

Related to Figure 3

DOCK8 knockdown leads to enlarged lysosomes **A**, Immunofluorescence staining of Lamp1 (green) in nontargeting control and DOCK8 knockdown cells (DOCK8si1 and DOCK8si2) in 6741-P, mKPC, and L3.6 cells. Scale bar 10 μ m. DOCK8 immunoblotting in **B**, 6741-P, **E**, mKPC, and **H**, L3.6 DOCK8 knockdown cells. Quantitation of average lysosome area (μ m²) in **C**, 6741-P, **F**, mKPC, and **I**, L3.6 DOCK8 knockdown cells. Quantitation of average lysosomes per cells in **D**, 6741-P (NT control n=99 cells, DOCK8si1 n=101 cells, DOCK8si2 n=97 cells), **G**, mKPC (NT control n=149 cells, DOCK8si1 n=114 cells, DOCK8si2 n=155 cells), and **J**, L3.6 DOCK8 knockdown cells (NT control n=178 cells, DOCK8si1 n=100 cells, DOCK8si2 n=105 cells). Graphs show the mean \pm S.E.M of at least three independent biological replicates. P-values were calculated using a Student's t-test. ns, p > .05; *, p \leq 0.05; **, p < 0.01; ***, p < 0.001; ****, p \leq 0.0001. **K**, Histogram showing frequency distribution of lysosome area (μ m²) in DOCK8 knockdown versus nontargeting (NT) control iKRAS^{G12D} cells, demonstrating an increase in the percentage of very large lysosomes following DOCK8 knockdown (iKRAS^{G12D} NT control n=168 cells, DOCK8 knockdown n=137 cells). **L**, Immunoblotting of 6741-P and L3.6 cells following DOCK8 knockdown. **M**, Transmission electron microscopy of L3.6 cells following DOCK8 knockdown. White arrows indicate lysosome compartments, which are enlarged in the DOCK8 knockdown cells. Scale bar 2 μ m. **N**, Images of lysotracker labeled lysosomes (red) in mKPC cells following DOCK8 knockdown. Scale bar 10 μ m. **O**, Immunoblotting of mKPC cells following DOCK8 knockdown. GAPDH serves as loading control, and area quantitation of average lysotracker-labeled lysosomes (μ m²). **P**, Images of lysotracker labeled lysosomes (red) in 6741-P cells following DOCK8 knockdown. Scale bar 10 μ m. **Q**, Immunoblotting of 6741-P cells following DOCK8 knockdown. GAPDH serves as loading control, and area quantitation of lysotracker-labeled lysosomes (μ m²). **R**, Immunofluorescence staining of LAMP1 in iKRAS^{G12D} cells cultured with doxycycline (KRAS^{G12D}) (1 μ g/ml) or following 72-hour doxycycline withdrawal (WT). Scale bar 20 μ m. Quantitation of **S**, Average lysosome area (μ m²), and **T**, Average lysosomes per cell (from **R**). **U**, Lysotracker labeling of iKRAS^{G12D} cells cultured with doxycycline (KRAS^{G12D}) (1 μ g/ml) or following 72-hour doxycycline withdrawal (WT). Scale bar 20 μ m. **V**, Quantitation of lysotracker mean fluorescence intensity fold change. Lysosome motility is reduced following DOCK8 knockdown. **W**, Track displacement of lysosomes over five minutes in LAMP1-mCherry labeled L3.6 cells. Tracks are pseudocolored to represent track length, 1 cell is shown. N=3 cells per condition in each of three independent experiments. Scale bar 5 μ m **X**, DOCK8 immunoblotting confirming DOCK8 knockdown in L3.6 cells. GAPDH serves as a loading control. **Y**, Quantitation of lysosome mean speed (of cells in **W**). **Z**, Quantitation of maximum lysosome distance traveled (of cells in **W**). Graphs show the mean \pm S.E.M of three independent biological replicates. P-values were calculated using a Student's t-test. ns, p > .05; *, p \leq 0.05; **, p < 0.01; ***, p < 0.001; ****, p \leq 0.0001.




Figure S6. DOCK8 depletion reduces lysosomal actin without altering global lysosome function

Related to Figure 4

A, Immunofluorescence staining of LAMP1 (green) and actin (red) in mKPC cells following DOCK8 knockdown. Scale bar 10 μ m. Quantitation in Fig. 4C. **B**, Immunoblotting validating DOCK8 knockdown in mKPC cells. **C**, Images of Rhodamine G-actin (red) nucleation at LAMP1-GFP (green) labeled lysosomes in 6741-P NT control and DOCK8 knockdown (DOCK8siP) cells. Scale bar 10 μ m. **D**, Immunoblotting validating DOCK8 knockdown in 6741-P cells. GAPDH serves as a loading control. **E**, Quantitation of Rhodamine G-actin fluorescence intensity overlapping with lysosomes (LAMP1-GFP). Nontargeting control n=47 cells, DOCK8siP n=59 cells. **F-H** Immunoblotting of EGFR degradation assay in **F**, 6741-P, **G**, L3.6, and **H**, Panc04.03 cells following DOCK8 knockdown (DOCK8siP) and treatment with 50ng/ml EGF for the indicated times. GAPDH serves as loading control. **I**, Images of DQ-BSA (green) and TMR-Dextran (red) in 6741-P cells following DOCK8 knockdown (DOCK8siP). Quantitation of **J**, DQ-BSA degradation (green, area per cell). **K**, Quantitation of macropinocytosis of TMR-Dextran (red, area per cell). Nontargeting control, n=252 total cells; DOCK8 KD, n=211. **L**, DQ-BSA fluorescence normalized to Macropinocytosis of TMR-Dextran. **M**, Images of lysotracker labeled lysosomes in mKPC cells following DOCK8 knockdown. Quantitation of lysotracker mean fluorescence intensity in **N**, mKPC (nontargeting control n= 414 total cells; DOCK8 KD, n= 496), and **O**, 6741-P cells (Images in S5P). Scale bars, 20 μ m (**I**, **M**). Graphs show the mean \pm S.E.M of three independent biological replicates. P-values were calculated using a Student's t-test. ns, p > .05; *, p \leq 0.05; **, p < 0.01; ***, p < 0.001; ****, p \leq 0.0001.




Figure S7. DOCK8 promotes pancreatic cancer cell invasion via cathepsin B

Related to Figure 4, 5

A, Images of Magic Red Cathepsin B fluorescence (red) indicating decreased active cathepsin B in mKPC, L3.6, Capan1, and Panc04.03 (immunoblot on figure 3A) cells following DOCK8 knockdown with a DOCK8siP. Scale bars, 50 μ m. **B**, Immunoblotting of DOCK8 in cells in **A** confirming DOCK8 knockdown. GAPDH serves as loading control. **C**, Images of Magic Red Cathepsin B fluorescence (red) indicating decreased active cathepsin B in mKPC, 6741-P, and L3.6 following DOCK8 knockdown with individual DOCK8si1, DOCK8si2, or nontargeting control. Scale bars, 20 μ m. **D**, Quantitation of Magic Red Cathepsin B fluorescence intensity in **C** (mKPC NT control n=411 cells, DOCK8si1 n=471 cells, DOCK8si2 n=441 cells; 6741-P NT control n=220 cells, DOCK8si1 n=247 cells, DOCK8si2 n=276 cells; L3.6 NT control n=263 cells, DOCK8si1 n=249 cells, DOCK8si2 n=272 cells). **E**, Images of Magic Red Cathepsin B fluorescence (red) in control and DOCK8 CRISPR knockout mKPC cells. Scale bars, 20 μ m. **F**, Quantitation of Magic Red Cathepsin B fluorescence intensity in **E** (Control clone 1 n= 404 cells; Control clone 2 n= 509 cells; Control clone 3 n= 292 cells; DOCK8 KO clone 1 n=630 cells; DOCK8 KO clone 2 n= 397 cells; DOCK8 KO clone 3 n= 683 cells). **G**, Immunoblotting of cathepsins in mKPC, (DOCK8, cathepsin B, D, L, and GAPDH), L3.6, and Capan1 cells (DOCK8, cathepsin B, D, and GAPDH) following DOCK8 knockdown. Quantified in figure 4**G**. **H**, Immunoblotting of cathepsin B in mKPC, 6741-P, and L3.6 cells following DOCK8 knockdown with (DOCK8si1, DOCK8si2, and DOCK8siP). **I**, Relative cathepsin B mRNA levels by qRT-PCR in DOCK8 knockdown cells from **H**. **J**, Quantitation of cathepsin B protein fold change normalized to GAPDH and nontargeting control in cells from **H**. **K**, Protease arrays for secreted proteases in conditioned media from DOCK8 knockdown (DOCK8siP) 6741-P cells. Quantitation in figure 5**A**. **L**, Images of cleaved DQ-Collagen (green) and nuclei (Hoechst, blue). mKPC Cells were seeded on coverslips coated with DQ-Collagen/Matrigel (top images) or DQ-Collagen/Gelatin mix (bottom images) following DOCK8 knockdown and were allowed to degrade ECM for two days. DOCK8 knockdown reduced ECM degradation. Quantified in figure 5**D**, **E**. Scale bars, 20 μ m. **M**, Cathepsin B is required for ECM degradation. Images of cleaved DQ-collagen (green) by mKPC cells seeded on a DQ-collagen substrate with gelatin for two days following overnight treatment with the cathepsin inhibitor CA-074ME (20 μ M) or DMSO as control. Scale bars, 20 μ m. **N**, Quantitation of cleaved DQ-Collagen in the indicated cells. Cells were allowed to degrade ECM in the presence of CA-074ME for two days (DMSO, n= 208 total cells; CA-074ME, n=314). **O**, Transwell cell invasion of 6741-P cells following mCherry or cathepsin B-mCherry expression and overnight treatment with CA-074ME (20 μ M) or DMSO control. Cells were seeded on Matrigel coated transwell filters in the presence of CA-074ME and allowed to invade for 20 hours towards a high serum gradient. A total of 1500 cells were counted per condition across three experiments. Graphs show the mean \pm S.E.M of three independent biological replicates. P-values were calculated using a Student's t-test. ns, p > .05; *, p \leq 0.05; **, p < 0.01; ***, p < 0.001; ****, p \leq 0.0001.